Value
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 4.8 |
| P/S | 7.8 |
| EV/EBITDA | 2.1 |
| Fwd P/E | 7.8 |
| PEG | 5.5 |
| Analyst target | 6.0 |
- ▸Forward P/E: 15.7x
- ▸PEG: 1.37
ABT · Why this verdict
Why Abbott Laboratories (ABT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company has delivered at or fractionally above consensus EPS in each of the last four reported quarters — the most recent an in-line result, followed by a slight beat, then two further in-line quarters — demonstrating a pattern of reliable guidance discipline that consistently avoids investor disappointment. Earnings | EPS continues to come in within ±1% of consensus for the next two reported quarters; guidance is maintained or raised. | →Stable |
| CounterA nearly flat average EPS surprise of 0.25% provides minimal positive catalyst energy; without meaningful beats, the stock may struggle to attract the incremental buying needed to resolve the current price downtrend. | ||
The stock trades below its 200-day moving average, which is itself declining at -5.0% per month in a confirmed downtrend, meaning the intermediate-term price trend is working against holders and entry ahead of a technical reversal carries timing risk. Momentum breakdown | This pillar is invalidated if the price recovers above $95.00 and the 200-day moving average slope turns positive for 4 consecutive weeks. | →Stable |
| CounterMACD is improving despite the death cross formation, and RSI at 57 is not approaching oversold territory — the downtrend may be in a late stage rather than accelerating further. | ||
A put/call ratio of 12.44 indicates that options market participants are aggressively hedging or expressing bearish views at an extreme level relative to bullish positioning, representing significant tail-risk sentiment against the stock. Key risks | This pillar is invalidated if the put/call ratio compresses below 3.0, indicating the hedging overhang has materially unwound. | →Stable |
| CounterAn extreme put/call ratio can also reflect institutional protective hedges on large long positions rather than outright bearish bets; if the underlying business quality (Piotroski score of 7 out of 9) remains intact, the ratio may normalize without a commensurate price decline. | ||
With 18.3% headroom to the analyst price target of $104.89 from the current price of $88.67 and a risk/reward of roughly 4-to-1 in favor of upside, the setup offers a meaningful return potential relative to the indicated downside. Price targets | Price closes toward the analyst price target of $104.89 over a 12-month period; consensus targets hold or are revised upward. | →Stable |
| CounterInternational sales account for 61% of revenues, introducing currency and regulatory risks that could cause analysts to cut targets if international demand softens; concentrated international exposure means analyst upside estimates may be revised away before the stock reaches target. | ||
The company has delivered at or fractionally above consensus EPS in each of the last four reported quarters — the most recent an in-line result, followed by a slight beat, then two further in-line quarters — demonstrating a pattern of reliable guidance discipline that consistently avoids investor disappointment.
→StableEarnings
- Expectation
- EPS continues to come in within ±1% of consensus for the next two reported quarters; guidance is maintained or raised.
CounterA nearly flat average EPS surprise of 0.25% provides minimal positive catalyst energy; without meaningful beats, the stock may struggle to attract the incremental buying needed to resolve the current price downtrend.
The stock trades below its 200-day moving average, which is itself declining at -5.0% per month in a confirmed downtrend, meaning the intermediate-term price trend is working against holders and entry ahead of a technical reversal carries timing risk.
→StableMomentum breakdown
- Expectation
- This pillar is invalidated if the price recovers above $95.00 and the 200-day moving average slope turns positive for 4 consecutive weeks.
CounterMACD is improving despite the death cross formation, and RSI at 57 is not approaching oversold territory — the downtrend may be in a late stage rather than accelerating further.
A put/call ratio of 12.44 indicates that options market participants are aggressively hedging or expressing bearish views at an extreme level relative to bullish positioning, representing significant tail-risk sentiment against the stock.
→StableKey risks
- Expectation
- This pillar is invalidated if the put/call ratio compresses below 3.0, indicating the hedging overhang has materially unwound.
CounterAn extreme put/call ratio can also reflect institutional protective hedges on large long positions rather than outright bearish bets; if the underlying business quality (Piotroski score of 7 out of 9) remains intact, the ratio may normalize without a commensurate price decline.
With 18.3% headroom to the analyst price target of $104.89 from the current price of $88.67 and a risk/reward of roughly 4-to-1 in favor of upside, the setup offers a meaningful return potential relative to the indicated downside.
→StablePrice targets
- Expectation
- Price closes toward the analyst price target of $104.89 over a 12-month period; consensus targets hold or are revised upward.
CounterInternational sales account for 61% of revenues, introducing currency and regulatory risks that could cause analysts to cut targets if international demand softens; concentrated international exposure means analyst upside estimates may be revised away before the stock reaches target.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Abbott Laboratories delivers with exceptional consistency — all four recent quarters within a fraction of a percent of consensus — and offers 18.3% headroom to the analyst price target with a roughly 4-to-1 favorable risk/reward; the principal headwinds are a confirmed price downtrend and an unusually extreme put/call ratio that warrants monitoring before adding exposure.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 4.1 |
| ROA | 3.7 |
| Gross margin | 7.3 |
| Op margin | 5.4 |
| Net margin | 7.0 |
| Current ratio | 5.2 |
| FCF quality | 7.1 |
| Moat | 7.0 |
| Piotroski F | 7.8 |
- ▸Strong Piotroski F-Score: 7/9
Growth
2.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.4 |
| EPS growth | 0.0 |
Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.6 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 1.6 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -5.1%/30d — confirmed downtrend
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 7.5 |
| Price target | 7.9 |
- ▸LLM news sentiment: +0.70 (n=6)
- ▸Analyst upside: 22%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Negligible insider buying — $1,301,477 (0.001% of mkt cap)
Peer rank
4.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.6 |
| quality rank | 7.8 |
| growth rank | 4.4 |
- ▸Best-in-class margins
Technical
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.4 |
| 52w position | 4.0 |
| gap | 5.0 |
Risk (lower is worse)
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.3 |
| days to cover | 9.1 |
| volatility | 5.5 |
| put call | 9.2 |
| implied vol | 5.7 |
| beta | 9.4 |
| debt equity | 7.1 |
| news risk | 5.5 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 2.6 |
| dividend safety | 6.0 |
| news activity | 8.0 |
- ▸Earnings in 13 days
- ▸Dividend: 264.0%
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:6.2>=5.5
- INSIDER:OK
- NEWS_BOOST:ANALYST:0.70
- NEWS_BOOST:ANALYST_CLUSTER(5)
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.2<1.5@spot
Warning (3)
- DEATH_CROSS:momentum=6.2>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
1.16
Upside
+10.1%
Downside
8.7%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 64
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Sentiment at 7.9) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:1.2<1.5@spot) reinforce the read. Current asymmetry R:R is 1.16 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 7.9, Risk (lower is worse) at 7.6, and Momentum at 6.2; the weakest are Growth at 2.2, Technical at 2.4, and Peer rank at 4.2. The V9 engine flagged 1 failed gate with 3 warnings, producing an asymmetric reward-to-risk of 1.16 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Consistent Earnings Delivery Streak
Trip ifEPS surprise falls below -3% for 2 consecutive quarters.
- P2Confirmed Price Downtrend Below 200ma
Trip ifPrice recovers above $95.00 and stays above for 4 consecutive weeks while the 200-day moving average slope turns positive.
- P3Extreme Put Call Ratio Hedge Demand
Trip ifPut/call ratio falls below 3.0 for 2 consecutive weeks.
- P4Favorable Risk Reward Analyst Upside
Trip ifAnalyst consensus price target falls below $95.00, reducing implied upside to less than 7% from current levels.